Back to Peptides

CJC-1295 (without DAC)

Well Studied

Short-Acting Growth Hormone Releasing Hormone Analog

Dose 100-300mcg per injection
Frequency 2-3 times daily (morning, post-workout optional, bedtime)
Cycle 12-16 weeks
Storage Lyophilized: 2-8°C refrigerated; Reconstituted: 2-8°C refrigerated, use within 30 days
Accumulation Plotter

Synthetic growth hormone releasing hormone analog with short half-life enabling pulsatile GH secretion patterns resembling natural physiology. Unlike CJC-1295 with DAC, this version preserves natural GH pulsatility without continuous elevation.

Mechanism of Action

Binds GHRH receptors on somatotroph cells in the pituitary gland, stimulating cAMP production and physiological GH pulses. The brief 30-minute half-life allows pulsatile release versus prolonged elevation.

Key Benefits

  • Preserves natural GH pulsatility
  • Minimal side effects
  • No receptor desensitization
  • Precise GH release control
  • 4x greater receptor affinity than native GHRH
Molecular Weight
3,367.97 Da
Chain Length
30 amino acids
Type
GHRH analog
Amino Acid Sequence
One-letter: YADAIFTNSYRKVLAQLSARKLLQDILSRK
H₂N
Y 1
O ‖ C
N
A 2
O ‖ C
N
D 3
O ‖ C
N
A 4
O ‖ C
N
I 5
O ‖ C
N
F 6
O ‖ C
N
T 7
O ‖ C
N
N 8
O ‖ C
N
S 9
O ‖ C
N
Y 10
O ‖ C
N
R 11
O ‖ C
N
K 12
O ‖ C
N
V 13
O ‖ C
N
L 14
O ‖ C
N
A 15
O ‖ C
N
Q 16
O ‖ C
N
L 17
O ‖ C
N
S 18
O ‖ C
N
A 19
O ‖ C
N
R 20
O ‖ C
N
K 21
O ‖ C
N
L 22
O ‖ C
N
L 23
O ‖ C
N
Q 24
O ‖ C
N
D 25
O ‖ C
N
I 26
O ‖ C
N
L 27
O ‖ C
N
S 28
O ‖ C
N
R 29
O ‖ C
N
K 30
COOH
Tyr
1

Tyrosine

Position 1

Ala
2

Alanine

Position 2

Asp
3

Aspartic Acid

Position 3

Ala
4

Alanine

Position 4

Ile
5

Isoleucine

Position 5

Phe
6

Phenylalanine

Position 6

Thr
7

Threonine

Position 7

Asn
8

Asparagine

Position 8

Ser
9

Serine

Position 9

Tyr
10

Tyrosine

Position 10

Arg
11

Arginine

Position 11

Lys
12

Lysine

Position 12

Val
13

Valine

Position 13

Leu
14

Leucine

Position 14

Ala
15

Alanine

Position 15

Gln
16

Glutamine

Position 16

Leu
17

Leucine

Position 17

Ser
18

Serine

Position 18

Ala
19

Alanine

Position 19

Arg
20

Arginine

Position 20

Lys
21

Lysine

Position 21

Leu
22

Leucine

Position 22

Leu
23

Leucine

Position 23

Gln
24

Glutamine

Position 24

Asp
25

Aspartic Acid

Position 25

Ile
26

Isoleucine

Position 26

Leu
27

Leucine

Position 27

Ser
28

Serine

Position 28

Arg
29

Arginine

Position 29

Lys
30

Lysine

Position 30

N-terminus C-terminus
Hydrophobic
Polar
Positive (+)
Negative (-)
Modified

Growth Hormone

  • Natural GH Pulse Restoration

    Restores natural GH pulsatility patterns in aging individuals.

  • IGF-1 Enhancement

    Elevates IGF-1 through enhanced GH secretion.

  • Pituitary Support

    Supports pituitary axis without suppression of natural function.

Anti-Aging

  • Muscle Mass Preservation

    Supports maintenance of lean muscle mass through GH elevation.

  • Bone Density Maintenance

    Supports bone health through GH-mediated pathways.

  • Skin Elasticity

    Improvements in skin quality through collagen synthesis.

Recovery

  • Exercise Recovery

    Enhanced recovery from training through GH elevation.

  • Sleep Quality

    Improved sleep architecture with bedtime dosing.

Subcutaneous injection is the only effective route. Best administered on empty stomach, 30+ minutes away from food.

GoalDoseFrequencyRoute
Anti-Aging/Wellness100mcg2x daily (morning and bedtime)SubQ
Body Composition100-150mcg3x daily (morning, post-workout, bedtime)SubQ
Maximum GH Release200mcg2-3x daily with GHRPSubQ
Sleep Enhancement100-200mcgOnce at bedtimeSubQ

Reconstitution Instructions

Materials Needed:
  • Bacteriostatic water
  • Insulin syringes (29-31 gauge)
  • Alcohol swabs
  • Sterile work surface
  1. 1 Clean vial tops with alcohol pad and allow to dry
  2. 2 Draw bacteriostatic water slowly
  3. 3 Inject water along vial side
  4. 4 Gently roll to mix—avoid vigorous shaking
  5. 5 Verify solution clarity; cloudiness indicates degradation
  6. 6 Label with date and concentration
  7. 7 Refrigerate immediately, use within 30 days
Ipamorelin

Complementary GH release via different receptor pathways. Popular combination.

synergistic
GHRP-6

Amplifies GH pulse when combined.

synergistic
GHRP-2

Potent combination maximizing GH through dual pathways.

synergistic
Hexarelin

Can combine but watch for excessive GH elevation.

monitor
CJC-1295 with DAC

Choose one variant based on desired release kinetics.

avoid
Tesamorelin

Both are GHRH analogs; combining offers no additional benefit.

monitor
MK-677

Different mechanisms; continuous ghrelin versus pulsatile GHRH.

compatible
Day 1-7

Improved sleep quality; vivid dreams from enhanced REM

Week 2-4

Enhanced workout recovery, reduced muscle soreness, better pumps

Week 4-8

Noticeable skin improvements, minor body composition shifts

Week 8-12

Significant lean gains, fat loss, improved joint comfort

Week 12+

Continued gradual improvements in composition and well-being

Common Side Effects

  • Generally well-tolerated at recommended doses
  • Temporary facial flushing/warmth (5-10 minutes post-injection)

Stop Signs - Discontinue if:

  • Persistent joint pain or carpal tunnel symptoms
  • Significant water retention or edema
  • Unexplained headaches or vision changes
  • Extreme fatigue or lethargy
  • Allergic reaction signs at injection sites

Contraindications

  • Active cancer (due to growth-promoting effects)
  • Diabetic retinopathy
  • Severe kidney disease
  • Pregnancy or breastfeeding

Good Signs

  • Vendor provides certificates of analysis (>98% purity)
  • Proper cold-chain shipping with ice packs/refrigeration
  • Vacuum-sealed vials showing pressure seal integrity
  • White/off-white lyophilized powder

Warning Signs

  • Verify expiration dates; lyophilized peptides stable ~2 years if stored properly

Bad Signs

  • Pre-reconstituted solutions—peptide degrades rapidly
  • Discolored powder (yellow/brown indicates degradation)
  • Cloudy solution after reconstitution
  • Pharmacokinetics of Modified GRF(1-29) in Healthy Adults
    (2006)

    Human study with 100-200mcg single dose in 12 subjects showed rapid absorption with peak GH at 15-30 minutes; established half-life and optimal frequency.

  • Growth Hormone Pulsatility with Mod GRF 1-29
    (2008)

    Human study with 100mcg 3x daily for 30 days in 24 subjects preserved natural GH pulsatility patterns with no pituitary desensitization.

  • Comparative Analysis: CJC-1295 vs Native GHRH
    (2010)

    In vitro and human receptor binding assays showed 4x greater receptor affinity than native GHRH with enhanced enzymatic degradation resistance.

  • Long-term Safety Profile of Modified GRF Analogs
    (2015)

    Animal model with 6 months daily administration showed no significant pituitary morphology or function changes supporting chronic safety.

Disclaimer

This information is for educational and research purposes only. Consult a healthcare professional before use.